Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Pete Stavropoulos

Welcome to the Cantor Global Healthcare Conference. I am Pete Stavropoulos, biotech analyst at Cantor . With us, we have Novavax, and I’m pleased to introduce the company. So let’s start off with a brief introduction of yourselves and a brief description of the company.

John Jacobs
President, CEO & Director

Thank you, John Jacobs, CEO.

Ruxandra Draghia-Akli
Executive VP and Head of Research & Development

I’m Ruxandra Draghia, Head of R&D.

James Kelly
Executive VP, CFO & Treasurer

And Jim Kelly, I’m the CFO. Thanks for having us, by the way.

Pete Stavropoulos

Well, thank you for joining us.

John Jacobs
President, CEO & Director

Thanks for having us, Pete. And look, we lead Novavax. We’re an innovative biotech that has a unique technology platform. We focus on vaccine development. Over the last 2.5 years, we’ve taken the company on quite a significant journey post pandemic, where we’ve converted it together as a leadership team to an organization that’s focused on driving our technology forward to create value. So we were a company that had one product, which emerged from the tech platform to help take on the global pandemic.

The company had built a vertical integrated structure that came with high expense and great opportunity. Through the pandemic, they generated a successful vaccine, but now we’ve converted the company by shrinking down that expense base, really cleaning up the balance sheet and the P&L, strengthening our cash runway while maintaining our capabilities and focusing on multiple opportunities for value creation